期刊
LANCET
卷 390, 期 10106, 页码 1996-2011出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30378-6
关键词
-
资金
- Janssen Cilag
- Novartis
- Roche
- Sanofi-Aventis
- Abbvie
- GlaxoSmithKline
- Bailleul
- Astellas
- Galderma
- Bayer
- Pierre Fabre
- Expanscience
- Cephalon
- Boehringer Ingelheim
During the past decade, major advances have been made in the accurate diagnosis of severe cutaneous adverse reactions (SCARs) to drugs, management of their manifestations, and identification of their pathogenetic mechanisms and at-risk populations. Early recognition and diagnosis of SCARs are key in the identification of culprit drugs. SCARS are potentially life threatening, and associated with various clinical patterns and morbidity during the acute stage of Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reactions with eosinophilia and systemic symptoms, and acute generalised exanthematous pustulosis. Early drug withdrawal is mandatory in all SCARs. Physicians' knowledge is essential to the improvement of diagnosis and management, and in the limitation and prevention of long-term sequelae. This Seminar provides the tools to help physicians in their clinical approach and investigations of SCARs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据